These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 33976166)

  • 1. A machine learning model for identifying patients at risk for wild-type transthyretin amyloid cardiomyopathy.
    Huda A; Castaño A; Niyogi A; Schumacher J; Stewart M; Bruno M; Hu M; Ahmad FS; Deo RC; Shah SJ
    Nat Commun; 2021 May; 12(1):2725. PubMed ID: 33976166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EstimATTR: A Simplified, Machine-Learning-Based Tool to Predict the Risk of Wild-Type Transthyretin Amyloid Cardiomyopathy.
    Castaño A; Heitner SB; Masri A; Huda A; Calambur V; Bruno M; Schumacher J; Emir B; Isherwood C; Shah SJ
    J Card Fail; 2024 Jun; 30(6):778-787. PubMed ID: 38065306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Machine Learning Identifies Plasma Metabolites Associated With Heart Failure in Underrepresented Populations With the
    Park JK; Petrazzini BO; Saha A; Vaid A; Vy HMT; Márquez-Luna C; Chan L; Nadkarni GN; Do R
    J Am Heart Assoc; 2023 Apr; 12(8):e027736. PubMed ID: 37042260
    [No Abstract]   [Full Text] [Related]  

  • 4. Cardiac Involvement in a Patient Cohort With Val30Met Mutation Transthyretin Amyloidosis.
    Ripoll-Vera T; Buades J; Cisneros E; Gómez Y; Núñez J; Raya M
    Rev Esp Cardiol (Engl Ed); 2019 Jan; 72(1):92-94. PubMed ID: 29223374
    [No Abstract]   [Full Text] [Related]  

  • 5. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.
    Maurer MS; Grogan DR; Judge DP; Mundayat R; Packman J; Lombardo I; Quyyumi AA; Aarts J; Falk RH
    Circ Heart Fail; 2015 May; 8(3):519-26. PubMed ID: 25872787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applying diagnosis support systems in electronic health records to identify wild-type transthyretin amyloid cardiomyopathy risk.
    Willis C; Watanabe AH; Hughes J; Nolen K; O'Meara J; Schepart A; Bruno M; Biskupiak J; Kawamoto K; Shara N; Kannampallil T
    Future Cardiol; 2022 May; 18(5):367-376. PubMed ID: 35098741
    [No Abstract]   [Full Text] [Related]  

  • 7. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey).
    Maurer MS; Hanna M; Grogan M; Dispenzieri A; Witteles R; Drachman B; Judge DP; Lenihan DJ; Gottlieb SS; Shah SJ; Steidley DE; Ventura H; Murali S; Silver MA; Jacoby D; Fedson S; Hummel SL; Kristen AV; Damy T; Planté-Bordeneuve V; Coelho T; Mundayat R; Suhr OB; Waddington Cruz M; Rapezzi C;
    J Am Coll Cardiol; 2016 Jul; 68(2):161-72. PubMed ID: 27386769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transthyretin Cardiac Amyloidosis Due to Homozygous Val122Ile Mutation in a Caucasian Man.
    Marrero Negrín N; Medina Gil JM; García Cruz ML; Jiménez Cabrera F
    Rev Esp Cardiol (Engl Ed); 2019 Dec; 72(12):1086-1088. PubMed ID: 31561982
    [No Abstract]   [Full Text] [Related]  

  • 9. Implementing clinical pathways to enable early diagnosis and treatment of wild-type transthyretin amyloid cardiomyopathy.
    Muller SA; Oerlemans MIFJ
    Eur J Heart Fail; 2023 Jun; 25(6):854-856. PubMed ID: 37191114
    [No Abstract]   [Full Text] [Related]  

  • 10. Longitudinal evolution of ventricular function and cardiac magnetic resonance imaging tissue characteristics in tafamidis-treated transthyretin amyloid cardiomyopathy.
    Dobner S; Bernhard B; Wieser M; Wahl A; Stark AW; Köchli V; Spano G; Boscolo Berto M; Johner C; Elchinova E; Tanner G; Safarkhanlo Y; Stortecky S; Schütze J; Hunziker Munsch L; Gräni C
    Amyloid; 2024 Jun; 31(2):145-147. PubMed ID: 38069637
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical characteristics and health care resource use of patients at risk for wild-type transthyretin amyloid cardiomyopathy identified by machine learning model.
    Bruno M; Sheer R; Reed C; Schepart A; Nair R; Simmons JD
    J Manag Care Spec Pharm; 2023 May; 29(5):530-540. PubMed ID: 37121249
    [No Abstract]   [Full Text] [Related]  

  • 12. Cardiac sympathetic denervation in wild-type transthyretin amyloidosis.
    Gimelli A; Aimo A; Vergaro G; Genovesi D; Santonato V; Kusch A; Emdin M; Marzullo P
    Amyloid; 2020 Dec; 27(4):237-243. PubMed ID: 32441155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease-Specific Biomarkers in Transthyretin Cardiac Amyloidosis.
    Hendren NS; Roth LR; Grodin JL
    Curr Heart Fail Rep; 2020 Jun; 17(3):77-83. PubMed ID: 32356182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ocular manifestations in hereditary transthyretin Gly67Glu amyloidosis.
    Leung KCP; Ko TCS
    Amyloid; 2019 Sep; 26(3):171-172. PubMed ID: 31135236
    [No Abstract]   [Full Text] [Related]  

  • 15. Disease-Modifying Treatments for Transthyretin Amyloidosis.
    Tushak ZJ; Cox SZ; Cei LF; Gwathmey KG; Shah KB
    J Cardiovasc Pharmacol; 2021 Nov; 78(5):e641-e647. PubMed ID: 34321398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Transthyretin-related amyloidotic cardiomyopathy: looking for the etiological treatment].
    Longhi S; Gagliardi C; Milandri A; Manuzzi L; Rapezzi C
    G Ital Cardiol (Rome); 2014 May; 15(5):293-300. PubMed ID: 25002169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular mechanisms and emerging therapies in wild-type transthyretin amyloid cardiomyopathy.
    Wu D; Chen W
    Heart Fail Rev; 2024 Mar; 29(2):511-521. PubMed ID: 38233673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable.
    Rubin J; Maurer MS
    Annu Rev Med; 2020 Jan; 71():203-219. PubMed ID: 31986086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transthyretin Cardiac Amyloidosis in Black Americans.
    Shah KB; Mankad AK; Castano A; Akinboboye OO; Duncan PB; Fergus IV; Maurer MS
    Circ Heart Fail; 2016 Jun; 9(6):e002558. PubMed ID: 27188913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac and peripheral vasomotor autonomic functions in hereditary transthyretin amyloidosis with non-Val30Met mutation.
    Koike H; Nakamura T; Nishi R; Ikeda S; Kawagashira Y; Iijima M; Katsuno M; Sobue G
    Amyloid; 2019; 26(sup1):13-14. PubMed ID: 31343285
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.